MedImmune to consider strategic alternatives

By Lisa Kerner

Charlotte, N.C., April 12 - MedImmune, Inc.'s board of directors authorized management to evaluate third-party interest in acquiring the company, according to a company news release.

In February, the company announced MedImmune intended to "aggressively implement its business plan." However, interest by other major pharmaceutical companies, pressure from shareholders and MedImmune's short-term stock price performance led the board to consider strategic alternatives with the aid of Goldman, Sachs & Co. and Dewey Ballantine LLP.

The Gaithersburg, Md.-based biotechnology company said it will not disclose further information until the review process is completed or it has entered into a definitive agreement for MedImmune to be acquired.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.